Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.31 USD

201.31
1,008,049

+0.84 (0.42%)

Updated Nov 5, 2024 11:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

What's in the Cards for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret are expected to drive third-quarter sales.

Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO

by Zacks Equity Research

Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.

AbbVie (ABBV) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

J&J Intends to Buy Residual Stake in Japanese Skincare Firm

by Zacks Equity Research

Johnson & Johnson (JNJ) makes a tender offer to buy the leftover stake in Japanese skincare firm Ci:z Holdings for about $2.05 billion in cash to strengthen its dermatology portfolio.

Sweta Killa headshot

Healthcare ETFs to Buy Ahead of Q3 Earnings

by Sweta Killa

The positive estimate revisions suggest continued outperformance for the healthcare ETFs.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $82.96, moving -1.55% from the previous trading session.

Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines

by Zacks Equity Research

Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.

Novartis Reports Positive Long-Term Data From Cosentyx Trials

by Zacks Equity Research

Novartis (NVS) announces encouraging five-year data from late-stage studies on Cosentyx for psoriatic arthritis and ankylosing spondylitis indications.

    EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq

    by Zacks Equity Research

    EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.

      J&J (JNJ) Beats Earnings & Sales Estimates in Q3, Ups View

      by Zacks Equity Research

      J&J (JNJ) beats estimates for both earnings and sales in the third quarter of 2018 and raises full-year forecast.

      Company News For Oct 15, 2018

      by Zacks Equity Research

      Companies In The News are: FRC,PNC,ABBV,INTC

      Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

      by Zacks Equity Research

      AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.

      Bristol-Myers Inks Deal and Invests $12 Million in Compugen

      by Zacks Equity Research

      Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.

      AbbVie Settles With Novartis to Delay Humira Biosimilar in US

      by Zacks Equity Research

      AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.

      AbbVie (ABBV) Stock Moves -1.54%: What You Should Know

      by Zacks Equity Research

      In the latest trading session, AbbVie (ABBV) closed at $93.11, marking a -1.54% move from the previous day.

      Neurocrine Inks Deal with Private Biotech to Make CNS Drugs

      by Zacks Equity Research

      Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.

      J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study

      by Zacks Equity Research

      J&J's (JNJ) Stelara induces clinical remission and response in ulcerative colitis patients who had failed prior therapy, per data from a phase III study.

      AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis

      by Zacks Equity Research

      AbbVie (ABBV) and Neurocrine receive Canadian approval for Orilissa, for the treatment of moderate to severe pain associated with endometriosis.

        Roche's Hemlibra Receives FDA Approval for Label Expansion

        by Zacks Equity Research

        Roche (RHHBY) obtains the FDA approval for the label expansion of Hemlibra for the treatment of adults and children suffering haemophilia A without factor VIII inhibitors.

          Gilead Announces Positive Data From Ongoing Biktarvy Study

          by Zacks Equity Research

          Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.

            Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors

            by Zacks Equity Research

            To boost its pipeline, Gilead (GILD) collaborates with HiFiBiO Therapeutics for the development of T-cell receptors.

              Here's Why J&J (JNJ) is a Good Bet in a Troubled Market

              by Zacks Equity Research

              A diversified portfolio, robust pipeline, strong growth of new drugs and a consistent dividend payout make Johnson & Johnson (JNJ) a good bet amid market turmoil as well as over the long term.

                Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again

                by Zacks Equity Research

                AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

                  Kinjel Shah headshot

                  Merck & Other Pharma Players Await FDA Decisions in October

                  by Kinjel Shah

                  FDA grants approval to 41 new treatments till the end of September.

                    The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental

                    by Zacks Equity Research

                    The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental